1. Home
  2. Bisphosphonates for Postmenopausal Osteoporosis

Bisphosphonates for Postmenopausal Osteoporosis

Author/s: 
Ensrud, KE, Crandall, CJ
Date Added: 
October 19, 2019
Journal/Publication: 
JAMA
Publisher: 
American Medical Association
Publication Date: 
October 17, 2019
URL: 
Bisphosphonates for Postmenopausal Osteoporosis
Type: 
Meta-analyses, Reviews, and Guidelines
Format: 
Article
DOI (1): 
10.1001/jama.2019.15781
PMID (1): 
31621799
Keywords 
post-menopausal osteoporosis
bisphosphonates
antiresorptive agents
MeSH 
Humans
female
ibandronic acid
Denosumab
zoledronic acid
Bone Density Conservation Agents
Raloxifene Hydrochloride
Risedronate Sodium
Alendronate
Osteoporosis, Postmenopausal
Selective Estrogen Receptor Modulators
creatinine
Progestins
Bone Density
Esophageal Achalasia
Barrett Esophagus
Hypocalcemia
Osteoclasts
Esophageal Stenosis
postmenopause
Goals
Groin
hip fractures
Diphosphonates
Bone Resorption
Gatroesophageal Reflux
Estrogens
vitamin D deficiency
Peptic Ulcer
risk reduction behavior
breast neoplasms
Biological Therapy
Femoral Fractures
Osteonecrosis
Hydroxyapatites
Minerals
pain

RPR Commentary

A short, sweet review of how, when, and for how long to treat postmenopausal osteoporosis.  James W. Mold, MD, MPH

Abstract

Bisphosphonates are the first-line pharmacologic treatment for postmenopausal osteoporosis and the most commonly prescribed medication for this condition.1 Bisphosphonates, classified as antiresorptive agents, have a very high affinity for bone mineral and bind to hydroxyapatite crystals on bony surfaces, where they inhibit osteoclast-mediated bone resorption.

Text Availability

Commercial full text (fees may apply)